177 related articles for article (PubMed ID: 17618725)
21. Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily.
Steckelbroeck S; Oyesanmi B; Jin Y; Lee SH; Kloosterboer HJ; Penning TM
J Pharmacol Exp Ther; 2006 Mar; 316(3):1300-9. PubMed ID: 16339391
[TBL] [Abstract][Full Text] [Related]
22. Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics.
Martin HJ; Breyer-Pfaff U; Wsol V; Venz S; Block S; Maser E
Drug Metab Dispos; 2006 Mar; 34(3):464-70. PubMed ID: 16381663
[TBL] [Abstract][Full Text] [Related]
23. Carbonyl-reducing enzymes as targets of a drug-immobilised affinity carrier.
Andrýs R; Zemanová L; Lenčo J; Bílková Z; Wsól V
Chem Biol Interact; 2015 Jun; 234():169-77. PubMed ID: 25595226
[TBL] [Abstract][Full Text] [Related]
24. Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C
Endo S; Morikawa Y; Kudo Y; Suenami K; Matsunaga T; Ikari A; Hara A
J Steroid Biochem Mol Biol; 2020 May; 199():105586. PubMed ID: 31926269
[TBL] [Abstract][Full Text] [Related]
25. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
O'connor T; Ireland LS; Harrison DJ; Hayes JD
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318
[TBL] [Abstract][Full Text] [Related]
26. Porcine aldo-keto reductase 1C subfamily members AKR1C1 and AKR1C4: Substrate specificity, inhibitor sensitivity and activators.
Endo S; Morikawa Y; Matsunaga T; Hara A; Nishinaka T
J Steroid Biochem Mol Biol; 2022 Jul; 221():106113. PubMed ID: 35398259
[TBL] [Abstract][Full Text] [Related]
27. Metabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamily.
Jin Y; Duan L; Chen M; Penning TM; Kloosterboer HJ
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):139-44. PubMed ID: 22210085
[TBL] [Abstract][Full Text] [Related]
28. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol.
Breyer-Pfaff U; Nill K
J Pharm Pharmacol; 2004 Dec; 56(12):1601-6. PubMed ID: 15563768
[TBL] [Abstract][Full Text] [Related]
29. In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone.
Tong Z; Chandrasekaran A; Li H; Rotshteyn Y; Erve JC; Demaio W; Talaat R; Hultin T; Scatina J
Drug Metab Dispos; 2010 May; 38(5):801-7. PubMed ID: 20173089
[TBL] [Abstract][Full Text] [Related]
30. Purification and characterization of two major forms of naloxone reductase from rabbit liver cytosol, new members of aldo-keto reductase superfamily.
Yamano S; Ichinose F; Todaka T; Toki S
Biol Pharm Bull; 1999 Oct; 22(10):1038-46. PubMed ID: 10549852
[TBL] [Abstract][Full Text] [Related]
31. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases.
Rosemond MJ; St John-Williams L; Yamaguchi T; Fujishita T; Walsh JS
Chem Biol Interact; 2004 Mar; 147(2):129-39. PubMed ID: 15013815
[TBL] [Abstract][Full Text] [Related]
32. Comparisons of (+/-)-benzo[a]pyrene-trans-7,8-dihydrodiol activation by human cytochrome P450 and aldo-keto reductase enzymes: effect of redox state and expression levels.
Quinn AM; Penning TM
Chem Res Toxicol; 2008 May; 21(5):1086-94. PubMed ID: 18402469
[TBL] [Abstract][Full Text] [Related]
33. The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man.
Malátková P; Havlíková L; Wsól V
Chem Biol Interact; 2014 Sep; 220():241-7. PubMed ID: 25063510
[TBL] [Abstract][Full Text] [Related]
34. The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoate induced esophageal squamous cell carcinoma cell death.
Li W; Hou G; Zhou D; Lou X; Xu Y; Liu S; Zhao X
Oncotarget; 2016 Apr; 7(16):21542-55. PubMed ID: 26934124
[TBL] [Abstract][Full Text] [Related]
35. Retention of NADPH-linked quinone reductase activity in an aldo-keto reductase following mutation of the catalytic tyrosine.
Schlegel BP; Ratnam K; Penning TM
Biochemistry; 1998 Aug; 37(31):11003-11. PubMed ID: 9692994
[TBL] [Abstract][Full Text] [Related]
36. Structural basis for substrate specificity in human monomeric carbonyl reductases.
Pilka ES; Niesen FH; Lee WH; El-Hawari Y; Dunford JE; Kochan G; Wsol V; Martin HJ; Maser E; Oppermann U
PLoS One; 2009 Oct; 4(10):e7113. PubMed ID: 19841672
[TBL] [Abstract][Full Text] [Related]
37. Carbonyl reduction of the potential cytostatic drugs benfluron and 3,9-dimethoxybenfluron in human in vitro.
Skálová L; Nobilis M; Szotáková B; Kondrová E; Savlík M; Wsól V; Pichard-Garcia L; Maser E
Biochem Pharmacol; 2002 Jul; 64(2):297-305. PubMed ID: 12123751
[TBL] [Abstract][Full Text] [Related]
38. Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro.
Takahashi RH; Bains OS; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2008 Jun; 36(6):991-4. PubMed ID: 18322072
[TBL] [Abstract][Full Text] [Related]
39. Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism.
Ji Q; Chang L; VanDenBerg D; Stanczyk FZ; Stolz A
Prostate; 2003 Mar; 54(4):275-89. PubMed ID: 12539226
[TBL] [Abstract][Full Text] [Related]
40. Purification and characterization of NAD-dependent morphine 6-dehydrogenase from hamster liver cytosol, a new member of the aldo-keto reductase superfamily.
Todaka T; Yamano S; Toki S
Arch Biochem Biophys; 2000 Feb; 374(2):189-97. PubMed ID: 10666297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
